查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836506

醫用氣體和設備：市場佔有率分析、行業趨勢、統計數據和成長預測（2025-2030 年）

Medical Gases And Equipment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計 2025 年醫用氣體和設備市場規模將達到 180.2 億美元，預計到 2030 年將達到 254.5 億美元，預測期內（2025-2030 年）的複合年成長率為 7.14%。

醫用氣體和設備-市場-IMG1

人口老化導致的治療需求不斷成長、新冠疫情后醫院基礎設施的穩步升級以及攜帶式濃縮器的快速技術創新，支撐了醫用氣體和設備市場的持續擴張。政府支持的氧氣彈性計劃、穿戴式感測器的小型化以及低全球暖化麻醉劑混合物的商業化將進一步促進銷量成長，而整合的氣體供應商則利用其規模優勢，在急性護理環境中獲得長期合約。設備製造商仍然分散，為補充性收購提供了空間，以豐富產品系列併提供地理多元化的服務，尤其是在高成長的亞太市場。持續向居家醫療的轉變正在擴大對氣瓶補充、現場緊湊型發電和人工智慧監控的需求，從而塑造了醫用氣體和設備市場的競爭格局。

全球醫用氣體和設備市場趨勢和洞察

家庭醫療保健和 POC氧氣療法的需求不斷成長

FlexO2 流量選擇器等技術在臨床部署後，使用戶主導的調節功能加倍，並將感知活動能力得分提高了 80 分。採用最佳化沸石床的可攜式濃縮器現在可實現 98.68% 的氧準確度，縮小了與固定式系統的性能差距。居家照護領域的複合年成長率為 13.01%，顯示這些改進正在滿足患者對熟悉環境的偏好。 CMS 的 2025 年支付更新使居家醫療費率提高了 2.5%，進一步支持了分散式照護模式。林德針對睡眠呼吸中止症患者的 AIRGENIOUS 研究降低了持續性正壓呼吸器 (CPAP) 不遵從的情況，並引入了對慢性病護理依從性的預測分析。

呼吸系統疾病盛行率不斷上升

慢性阻塞性肺病 (COPD) 仍然是氧氣使用的主要促進因素，佔三級醫院呼吸科病房的 44.5%。典型的床位氣體需求平均每年為 350 立方公尺氧氣和 325 立方公尺醫用空氣，與出院量和手術強度成正比。歐洲規劃部門已將醫用氣體系統升級納入國家呼吸策略，例如奧地利的《2025 年總體規劃》。疫情期間氧氣消耗激增的分析顯示，氧氣消費量增加了 20 倍，凸顯了供應基礎設施永久冗餘的必要性。波蘭的「健康需求地圖」計劃強調了呼吸系統疾病地圖如何指南醫院層面的氣體系統投資。

嚴格遵守多司法管轄區的 cGMP 和藥典

美國食品藥物管理局（FDA）的最終規則（將於2025年12月生效）將要求全面遵守現行的醫用氣體生產控制和標籤通訊協定，迫使供應商投資升級其填充和分析系統。香港將從2026年6月起將醫用氣體歸類為藥品，並為經銷商引入新的許可等級。同時修訂的規則將使基於ISO的器械品管與cGMP的明確規定相協調，促進全球標準的融合，同時增加跨境合規成本。

報告中分析的其他促進因素和限制因素

  1. 後疫情時代政府資助的氧氣基礎建設
  2. 可攜式/穿戴式濃縮器和感測器的小型化
  3. 長期居家氧氣療法的報銷限制

細分分析

到2024年，純醫用氣體將佔醫用氣體和設備市場的37.81%，反映出其在醫院和家庭環境中的重要治療應用。預計氧氣的複合年成長率將達到8.91%，這得益於居家醫療的日益普及和呼吸系統疾病的流行。醫用空氣、二氧化碳和氦氣/特種氣體可滿足手術氣腹、診斷和核磁共振成像的需求，但氦氣供應波動正在推高價格，並對醫院預算造成壓力。繼加州大學舊金山分校成功將氧化亞氮消耗量減少80-90%後，醫療機構正在轉向使用攜帶式氣瓶，並取消管道以減少廢棄物。

互補醫用氣體設備涵蓋壓縮機、氣缸和管路監控系統等多種領域。阿特拉斯·科普柯於2023年收購Medi-teknique，標誌著一項旨在拓展服務範圍並持續創造維護收入的整合。 BeaconMedaes的全球經銷商網路利用多模光纖環網實現即時警報功能，並將真空和歧管系統融入新建醫院。對永續性的日益關注正推動醫院採用低全球暖化潛勢（GWP）的麻醉劑混合物。歐洲監管機構已認可SEVOFLURANE的全球暖化潛勢值遠低於地DESFLURANE，促使供應商重新設計揮發性氣體的回收和清除系統。

到2024年，封裝式氧氣瓶的市場佔有率將保持45.79%，而隨著患者尋求更便捷的出行方式，以及醫療保健機構優先考慮經濟高效的慢性病護理模式，攜帶式氧氣濃縮器預計將以每年9.81%的速度成長。德克薩斯農工大學的計算設計表明，動態沸石結構可以在不犧牲純度的情況下減輕重量，並可調節氧氣流量以滿足不斷變化的患者需求。同時，林德在2024年獲得了59份小型現場氧氣發電廠訂單，這反映出醫院對自主供氧供給能力的興趣，以應對供應中斷的風險。

現場批量生產持續吸引尋求可預測單位成本的大型三級醫院，而批量液體供應則為需要超高純度的專科中心提供支援。對氣瓶備用的持續偏好確保了所有醫療模式的穩定需求，從而豐富了醫用氣體和設備市場的收益結構。

區域分析

受成熟的支付系統、嚴格的FDA監管以及可攜式製氧機的廣泛應用的推動，北美地區將佔2024年銷售額的35.87%。醫院透過現場大容量儲氧罐維持氧氣的冗餘生產，隨著CMS（醫療保險和居家醫療設備的採用率也持續成長。區域設備供應商受益於清晰的監管路徑，該路徑鼓勵創新，且沒有模糊的市場進入規則。

亞太地區13.51%的複合年成長率在所有地區中最高，這得益於大規模醫院擴建、人口老化以及政府對醫療基礎設施的大力投入。印度計畫新增17,800張病床，並制定了500億美元的醫療設備藍圖，支撐了管道系統和氣瓶需求的激增。中國自2024年起推出的支持性採購政策預計將在2025年釋放醫療設備支出，鞏固其作為該地區最大成長引擎的地位。林德和梅塞爾在印度和東南亞的空分裝置擴建項目，彰顯了供應商致力於維護區域供應穩定的決心。

歐洲仍然是一個關鍵市場，受嚴格的環境法規推動，這些法規正在加速低全球暖化潛勢麻醉劑的採用。英國國家醫療服務體系（NHS）逐步淘汰地DESFLURANE，對整個歐洲大陸的醫療機構產生了連鎖反應，迫使供應商調整配方，醫院升級復甦系統。液化空氣集團在法國、德國和巴西簽訂的低碳氧氣供應契約，凸顯了範圍三排放在公立醫院採購標準中日益重要的地位。

中東/非洲和南美洲是潛力巨大但仍處於萌芽階段的市場。對三級醫療機構的投資以及藥典標準的逐步統一將釋放更多機遇，但經濟波動和報銷機制的碎片化可能會在短期內阻礙其規模化發展。

其他福利：

  • Excel 格式的市場預測 (ME) 表
  • 3個月的分析師支持

目錄

第1章 引言

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章 市場狀況

  • 市場概況
  • 市場促進因素
    • 家庭醫療保健和 POC氧氣療法的需求不斷成長
    • 呼吸系統疾病增加
    • 後疫情時代政府資助的氧氣基礎設施
    • 可攜式/穿戴式濃縮器和感測器的小型化
    • 環保、低全球升溫潛勢麻醉氣體混合物的商業化
    • 人工智慧驅動的天然氣管道預測監控和庫存管理
  • 市場限制
    • 嚴格遵守多司法管轄區的 cGMP 和藥典
    • 長期居家氧氣療法的報銷限制
    • 散裝氣體處理中的職業安全責任和保險費用。
    • 氦氣供應的不確定性推高了特種氣體成本
  • 波特五力分析
    • 新進入者的威脅
    • 買家/消費者的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭對手之間的競爭強度

第5章市場規模及成長預測（單位：美元）

  • 按產品
    • 醫用氣體
      • 純醫用氣體
      • 氧
      • 氧化亞氮
      • 醫用空氣
      • 二氧化碳
      • 氦氣和特種氣體
      • 醫用氣體混合物
      • 生物空氣
    • 醫用氣體設備
      • 壓縮機
      • 圓柱
      • 軟管組件和閥門
      • 面罩和插管
      • 真空和抽吸系統
      • 歧管和管路系統
      • 警報和監控系統
  • 按方式
    • 現場批量發電
    • 封裝圓筒
    • 液體/散裝運輸
    • 可攜式濃縮器
  • 按用途
    • 治療
    • 診斷與影像診斷
    • 藥品製造和研究
    • 果凍和冷凍療法
    • 家庭醫療保健
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 居家醫療
    • 學術和研究機構
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲國家
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • GCC
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美

第6章 競爭態勢

  • 市場集中度
  • 市佔率分析
  • 公司簡介
    • Linde plc
    • Air Liquide
    • Air Products & Chemicals
    • Messer Group
    • Taiyo Nippon Sanso
    • Atlas Copco
    • BeaconMedaes
    • Amico Group
    • Matheson Tri-Gas
    • GCE Group
    • NOVAIR
    • Luxfer Gas Cylinders
    • Getinge AB
    • Dragerwerk AG
    • INOX Air Products
    • South African Oxygen（Afrox）
    • Gulf Cryo
    • Coregas Pty
    • SOL Group
    • Air Water Inc.
    • Invacare Corporation

第7章 市場機會與未來展望

簡介目錄
Product Code: 50695

The Medical Gases And Equipment Market size is estimated at USD 18.02 billion in 2025, and is expected to reach USD 25.45 billion by 2030, at a CAGR of 7.14% during the forecast period (2025-2030).

Medical Gases And Equipment - Market - IMG1

Rising therapeutic demand from aging populations, steady hospital infrastructure upgrades after COVID-19, and rapid innovation in portable concentrators underpin sustained expansion of the medical gases and equipment market. Government-supported oxygen resilience projects, miniaturization of wearable sensors, and the commercialization of low-GWP anesthetic blends further reinforce volume growth, while consolidated gas suppliers leverage scale to secure long-term contracts across acute-care settings. Equipment makers remain fragmented, creating space for bolt-on acquisitions that deepen product portfolios and geographically diversified service footprints, especially in high-growth Asia-Pacific markets. The continued shift toward home-based care amplifies cylinder refilling, small on-site generation, and AI-enabled monitoring demand, collectively shaping the competitive contours of the medical gases and equipment market.

Global Medical Gases And Equipment Market Trends and Insights

Rising Demand for Home Healthcare & POC Oxygen Therapy

Medicare's 36-month rental framework underpins predictable reimbursement, encouraging supplier investment in portable devices and reinforcing patient acceptance of at-home oxygen therapy.Technology such as FlexO2 flow selectors has doubled user-initiated adjustments, raising perceived activity capacity scores by 80 points after clinical deployment.Portable concentrators that use optimized zeolite beds now deliver 98.68% oxygen accuracy, narrowing the performance gap with stationary systems. A 13.01% CAGR in the home-care segment illustrates how these improvements align with patient preference for familiar environments. CMS's 2025 payment update, lifting home health rates by 2.5% adds further momentum to decentralized care models. Linde's AIRGENIOUS pilot among sleep-apnea users cut CPAP non-compliance, showcasing predictive analytics for chronic-care adherence.

Growing Prevalence of Respiratory Diseases

COPD remains the chief driver of oxygen admissions, representing 44.5% of respiratory ward volume in tertiary hospitals. Typical bed-based gas demand averages 350 m3 oxygen and 325 m3 medical air each year, scaling directly with discharge volumes and surgical intensity. European planners have already embedded medical gas system upgrades into national respiratory strategies, as shown in the Austrian Masterplan 2025. Analysis of pandemic surges revealed oxygen consumption rising up to 20-fold, anchoring the need for permanent redundancy in supply infrastructure. Poland's Maps of Health Needs initiative highlights how respiratory disease mapping guides investment in gas systems at hospital level.

Stringent Multi-Jurisdictional cGMP & Pharmacopeia Compliance

The FDA's final rule, effective December 2025, mandates full current good manufacturing practice and labeling protocols for medical gases, compelling suppliers to invest in upgraded filling and analytical systems. Hong Kong will classify medical gases as pharmaceutical products from June 2026, introducing a new licensing layer for distributors. Parallel amendments harmonize ISO-based device quality management with cGMP clarifications, raising cross-border compliance costs yet fostering global standard convergence.

Other drivers and restraints analyzed in the detailed report include:

  1. Government-Funded Oxygen Infrastructure Build-Outs Post-COVID
  2. Miniaturization of Portable/Wearable Concentrators & Sensors
  3. Limited Reimbursement for Long-Term Home Oxygen Therapy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pure Medical Gases captured 37.81% of the medical gases and equipment market in 2024, reflecting indispensable therapeutic use across hospitals and home settings. Oxygen is projected to record an 8.91% CAGR, aided by expanding home-care adoption and respiratory disease prevalence. Medical Air, Carbon Dioxide, and Helium & Specialty Gases serve surgical insufflation, diagnostics, and MRI needs, though helium supply volatility has driven price escalations that strain hospital budgets. Nitrous Oxide consumption is shifting toward portable cylinders as institutions remove piped lines to curb waste, following UCSF's 80-90% reduction success.

Complementary medical gas equipment ranges from compressors and cylinders to pipeline monitoring systems. Atlas Copco's 2023 Medi-teknique acquisition illustrates consolidation aimed at service breadth and recurring maintenance revenue. BeaconMedaes' global distributor network embeds vacuum and manifold systems within new hospital builds, leveraging multi-mode optical fiber ring networks for real-time alarm capabilities. A rising focus on sustainability is prompting hospitals to adopt low-GWP anesthetic blends. European regulators endorse sevoflurane over desflurane because of its far lower global-warming potential, nudging suppliers to re-engineer recovery and scavenging systems for volatile agents.

Packaged Cylinders retained a 45.79% share in 2024, yet Portable Concentrators are forecast to grow 9.81% annually as patients demand mobility and healthcare providers emphasize cost-effective chronic-care models. Computational design by Texas A&M shows that dynamic zeolite configurations can tailor oxygen flow to fluctuating patient needs, reducing weight without cutting purity. Meanwhile, Linde recorded 59 small on-site plant wins in 2024, reflecting hospital interest in self-reliant oxygen capacity to hedge against supply disruptions.

Bulk on-site generation continues to attract large tertiary hospitals seeking predictable unit costs, whereas liquid bulk delivery supports specialty centers with ultra-high purity requirements. The continued preference for cylinder backup ensures steady demand across every modality, cementing a diversified revenue mix within the medical gases and equipment market.

The Medical Gases and Equipment Market Report is Segmented by Product (Medical Gases [Pure Medical Gases, and More], and Medical Gas Equipment [Compressors, and More]), Modality (Bulk On-Site Generation, and More), Application (Therapeutic, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America contributed 35.87% of 2024 revenue, anchored by mature payer systems, strict FDA oversight, and widespread adoption of portable concentrators. Hospitals maintain redundant oxygen generation backed by on-site bulk tanks, while home-care penetration continues to rise as CMS refines reimbursement. Regional equipment vendors benefit from clear regulatory pathways that reward innovation without ambiguous market access rules.

Asia-Pacific is projected to grow at 13.51% CAGR, the highest among all regions, driven by large-scale hospital expansion, aging populations, and proactive government funding for medical infrastructure. India's planned capacity additions of 17,800 beds alongside a USD 50 billion medical device roadmap illustrate the underlying demand surge for pipeline systems and cylinders. China's supportive procurement policies post-2024 are expected to unlock medical device spending in 2025, reinforcing the region's status as the foremost growth engine. Air separation unit expansions by Linde and Messer across India and Southeast Asia signal supplier commitment to sustaining regional supply security.

Europe remains a major market, propelled by stringent environmental mandates that accelerate low-GWP anesthesia adoption. The NHS elimination of desflurane has cascaded across continental practice, compelling suppliers to reformulate and hospitals to upgrade recovery systems. Air Liquide's low-carbon oxygen supply contracts in France, Germany, and Brazil showcase the rising importance of Scope 3 emissions in public hospital procurement criteria.

Middle East & Africa and South America collectively represent high-potential but early-stage markets. Investments in tertiary care facilities and the gradual harmonization of pharmacopeia standards will unlock incremental opportunities, although economic volatility and reimbursement fragmentation temper near-term scale.

  1. Linde plc
  2. Air Liquide
  3. Air Products & Chemicals
  4. Messer Group
  5. Taiyo Nippon Sanso
  6. Atlas Copco
  7. Beckton Dickinson
  8. Amico Group
  9. Matheson Tri-Gas
  10. GCE Group
  11. NOVAIR
  12. Luxfer Gas Cylinders
  13. Getinge
  14. Dragerwerk AG
  15. INOX Air Products
  16. South African Oxygen (Afrox)
  17. Gulf Cryo
  18. Coregas Pty
  19. SOL Group
  20. Air Water Inc.
  21. Invacare

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Home Healthcare & POC Oxygen Therapy
    • 4.2.2 Growing Prevalence of Respiratory Diseases
    • 4.2.3 Government-Funded Oxygen Infrastructure Build-Outs Post-COVID
    • 4.2.4 Miniaturization of Portable/ Wearable Concentrators & Sensors
    • 4.2.5 Commercialization of Eco-Friendly Low-GWP Anaesthesia Gas Blends
    • 4.2.6 AI-Enabled Predictive Gas-Pipeline Monitoring & Inventory Control
  • 4.3 Market Restraints
    • 4.3.1 Stringent Multi-Jurisdictional cGMP & Pharmacopeia Compliance
    • 4.3.2 Limited Reimbursement for Long-Term Home Oxygen Therapy
    • 4.3.3 Workplace-Safety Liability & Insurance Costs for Bulk-Gas Handling
    • 4.3.4 Helium Supply Volatility Driving Up Specialty-Gas Costs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Product
    • 5.1.1 Medical Gases
      • 5.1.1.1 Pure Medical Gases
      • 5.1.1.1.1 Oxygen
      • 5.1.1.1.2 Nitrous Oxide
      • 5.1.1.1.3 Medical Air
      • 5.1.1.1.4 Carbon Dioxide
      • 5.1.1.1.5 Helium & Specialty Gases
      • 5.1.1.2 Medical Gas Mixtures
      • 5.1.1.3 Biological Atmosphere
    • 5.1.2 Medical Gas Equipment
      • 5.1.2.1 Compressors
      • 5.1.2.2 Cylinders
      • 5.1.2.3 Hose Assemblies & Valves
      • 5.1.2.4 Masks & Cannulas
      • 5.1.2.5 Vacuum & Suction Systems
      • 5.1.2.6 Manifold & Pipeline Systems
      • 5.1.2.7 Alarm & Monitoring Systems
  • 5.2 By Modality
    • 5.2.1 Bulk On-site Generation
    • 5.2.2 Packaged Cylinders
    • 5.2.3 Liquid/Bulk Delivery
    • 5.2.4 Portable Concentrators
  • 5.3 By Application
    • 5.3.1 Therapeutic
    • 5.3.2 Diagnostic & Imaging
    • 5.3.3 Pharmaceutical Manufacturing & Research
    • 5.3.4 Cryosurgery & Cryotherapy
    • 5.3.5 Home Healthcare
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Home Care Settings
    • 5.4.4 Academic & Research Institutes
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Linde plc
    • 6.3.2 Air Liquide
    • 6.3.3 Air Products & Chemicals
    • 6.3.4 Messer Group
    • 6.3.5 Taiyo Nippon Sanso
    • 6.3.6 Atlas Copco
    • 6.3.7 BeaconMedaes
    • 6.3.8 Amico Group
    • 6.3.9 Matheson Tri-Gas
    • 6.3.10 GCE Group
    • 6.3.11 NOVAIR
    • 6.3.12 Luxfer Gas Cylinders
    • 6.3.13 Getinge AB
    • 6.3.14 Dragerwerk AG
    • 6.3.15 INOX Air Products
    • 6.3.16 South African Oxygen (Afrox)
    • 6.3.17 Gulf Cryo
    • 6.3.18 Coregas Pty
    • 6.3.19 SOL Group
    • 6.3.20 Air Water Inc.
    • 6.3.21 Invacare Corporation

7 Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment